The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1;2) following the 200 EMCI subjects enrolled in the GO ADNl grant;3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects;4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan;5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.

Public Health Relevance

Alzheimer's disease (AD) causes cognitive impairment and dementia in millions of Americans and costs more than $100 billion/year in the USA. This ADNl project will provide new information which will greatly facilitate design of clinical treatment trials and will help develop new diagnostic techniques which identify AD at an early stage, ultimately leading to effective treatment and prevention of AD. REVIEW OF THE OVERALL PROGRAM

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AG024904-06
Application #
7983193
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Ryan, Laurie M
Project Start
2004-09-30
Project End
2015-08-31
Budget Start
2010-09-30
Budget End
2011-08-31
Support Year
6
Fiscal Year
2010
Total Cost
$8,000,000
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Cui, Xiaohong; Xiang, Jie; Wang, Bin et al. (2018) Integrating the Local Property and Topological Structure in the Minimum Spanning Tree Brain Functional Network for Classification of Early Mild Cognitive Impairment. Front Neurosci 12:701
Sanroma, Gerard; Benkarim, Oualid M; Piella, Gemma et al. (2018) Learning non-linear patch embeddings with neural networks for label fusion. Med Image Anal 44:143-155
Luk, Collin C; Ishaque, Abdullah; Khan, Muhammad et al. (2018) Alzheimer's disease: 3-Dimensional MRI texture for prediction of conversion from mild cognitive impairment. Alzheimers Dement (Amst) 10:755-763
Riedel, Brandalyn C; Daianu, Madelaine; Ver Steeg, Greg et al. (2018) Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer's Disease in the Aging Brain. Front Aging Neurosci 10:390
Luo, Xiao; Li, Kaicheng; Zeng, Qingze et al. (2018) Decreased Bilateral FDG-PET Uptake and Inter-Hemispheric Connectivity in Multi-Domain Amnestic Mild Cognitive Impairment Patients: A Preliminary Study. Front Aging Neurosci 10:161
Oltra-Cucarella, Javier; Sánchez-SanSegundo, Miriam; Ferrer-Cascales, Rosario et al. (2018) Cognition or genetics? Predicting Alzheimer's disease with practice effects, APOE genotype, and brain metabolism. Neurobiol Aging 71:234-240
Tao, Qiushan; Zhu, Haihao; Chen, Xi et al. (2018) Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease. J Alzheimers Dis 62:597-609
Rauchmann, Boris-Stephan; Schneider-Axmann, Thomas; Alexopoulos, Panagiotis et al. (2018) CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiol Aging 74:182-190
Valdés Hernández, Maria Del C; Reid, Stuart; Mikhael, Shadia et al. (2018) Do 2-year changes in superior frontal gyrus and global brain atrophy affect cognition? Alzheimers Dement (Amst) 10:706-716
Wang, Lijun; Tian, Ting; Alzheimer’s Disease Neuroimaging Initiative (2018) Gender Differences in Elderly With Subjective Cognitive Decline. Front Aging Neurosci 10:166

Showing the most recent 10 out of 1666 publications